Posted from: Friday, October 31, 2014 - 12:24 PM - Present

FDA Approves New Dosage Form of Abilify Maintena

September 29, 2014 – The US Food and Drug Administration (FDA) approved Abilify Maintena (aripiprazole) as prefilled syringes for extended-release injectable suspension manufactured by Ostuka and Lundbeck.  Abilify Maintena is a long-acting, once monthly treatment for schizophrenia administered via intramuscular injection.  Currently the Abilify Maintena Kit includes a vial of sterile water that has to be pulled into a syringe and injected into a vial of dried aripiprazole and mixed that must then be drawn into another syringe for injection by a healthcare professional.  The new dosage form is packaged with the active ingredient and the sterile water in separate sections that get mixed without having to be drawn into different syringes.  The prefilled syringes of Abilify Maintena are anticipated to be launched in January, 2015 in 300 mg and 400 mg strengths.

 

If you have any questions you can contact our Client Services Call Center at 1-877-723-6005.

 Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Prices referenced are estimates based on available data and are subject to change at the time a claim is processed. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

 

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Sunday, April 23, 2017 - 01:09 AM.